The genetic predisposition would also explain why certain ethnic groups may be more susceptible to the cancer onset with prolonged usage of PPARγ agonists even though TZDs are generally associated with protective effects against several common cancers [42,43]. The gene discussed is PPARG; the disease is cancer.